ReviewTheranostics2020
COVID-19: Progress in diagnostics, therapy and vaccination.
Review in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adherence to COVID-19 preventive measures in Sub-Saharan Africa during the 1st year of the pandemic: Pooled analysis of the International Citizen Project on COVID-19 (ICPCovid) surveys.Frontiers in public health · 2022Pooled it
- Pooled it
- The use of complementary and traditional medicine for the treatment of patients with COVID-19: A systematic review.Explore (New York, N.Y.)Pooled it
- Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.Clinical and translational medicine · 2021Trial
- Probiotics and Bacteriocins Against SARS-CoV-2: Therapeutic Frontiers and Mechanistic Insights.Probiotics and antimicrobial proteins · 2026Review
- An Examination of Mental Health Rates in Children During the First Year of the COVID-19 Pandemic: Findings from the National Health Interview Survey 2019-2020.Child psychiatry and human development · 2026Review
- Metagenomic next-generation sequencing reveals respiratory flora distribution in COVID-19.Scientific reports · 2025Article
- The Impact of Health Coverage, Race and Ethnicity on Utilization of Preventive Medical Care during the First Year of the Covid-19 Pandemic: Findings from the National Health Interview Survey 2019-2020.Journal of racial and ethnic health disparities · 2024Article
- Artificial intelligence empowering public health education: prospects and challenges.Frontiers in public health · 2024Article
- Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Factors Related to Low COVID-19 Vaccination Rate in Pregnant and Postpartum Women with and without COVID-19.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023Article
- The application of multi-walled carbon nanotubes modified pencil graphite electrode for voltammetric determination of favipiravir used in COVID-19 treatment.Monatshefte fur chemie · 2023Article
- Article
- COVID-19 Vaccines Adverse Reactions Reported to the Pharmacovigilance Unit of Beira Interior in Portugal.Journal of clinical medicine · 2022Article
- Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.Journal of translational medicine · 2022Article
- Analysis of trends in patent development for coronavirus detection, prevention, and treatment technologies in key countries.Journal of biosafety and biosecurity · 2022Review
- Discussion on China's anti-epidemic response based on the Protocol on Prevention and Control of Coronavirus Disease 2019 from Chinese Authority.The International journal of health planning and management · 2022Article
- Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.Iranian journal of basic medical sciences · 2022Article
- A global picture: therapeutic perspectives for COVID-19.Immunotherapy · 2022Review
- Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants.Diabetes & metabolic syndrome · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently become a pandemic. As the sudden emergence and rapid spread of SARS-CoV-2 is endangering global health and the economy, the development of strategies to contain the virus's spread are urgently needed. At present, various diagnostic kits to test for SARS-CoV-2 are available for use to initiate appropriate treatment faster and to limit further spread of the virus. Several drugs have demonstrated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.